Clarivate Reports Q3 2026 Results Following Life Sciences & Healthcare Divestiture
Clarivate (CLVT) reported third-quarter revenue of $481.6 million for continuing operations, a 9.2% year-over-year decrease primarily driven by inorganic disposals following the sale of its Life Sciences & Healthcare segment. Despite the top-line decline, the company achieved organic subscription growth of 1.5% and reported an adjusted diluted EPS of $0.21, up $0.03 from the previous year. The company's strategic shift is highlighted by a significant $488.4 million in net cash proceeds from its recent divestiture and aggressive debt reduction totaling $293.8 million year-to-date. While a $62.2 million non-cash goodwill impairment charge led to a reported net loss of $80.8 million, management remains optimistic about future growth, citing a 2.5-fold increase in AI API call volume and strong institutional adoption of its Web of Science Research Intelligence platform.
Tickers: $CLVT
Topics: EBITDA goodwill impairment net loss organic growth revenue
Read the full article at Motley Fool
Part of the story Cogent Communications Reports Q3 2026 Results with Improved EBITDA Margins and Wavelength Growth (22 articles)